Should I Buy ENLV? ENLV 2026 Analysis

Should You Buy Enlivex Therapeutics Ltd (ENLV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.160

1 Day change

52 Week Range

2.100

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: setup is low-conviction with no proprietary buy signals, no near-term catalysts, and major strategic/financing overhang.
Price is below the pivot (1.106) and still needs to reclaim it to improve the immediate technical picture.
Options positioning looks extremely call-heavy, but with essentially zero trading volume and ultra-high IV, it reads more like thin, speculative positioning than reliable bullish confirmation.

Technical Analysis

Trend/structure: Mixed-to-soft near-term; current price 1.06 sits below Pivot 1.106, implying sellers still have control of the immediate level.
Momentum: MACD histogram slightly positive (0.00227) but positively contracting → bullish momentum is fading rather than expanding.
RSI(6) ~50 (neutral) → no strong oversold bounce signal.
Moving averages: Converging → consolidation/indecision rather than a clean trend.
Key levels: Support S1=0.995 then S2=0.927; Resistance R1=1.217 then R2=1.285. A cleaner buy setup would typically come after reclaiming 1.106 and holding above it.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment (open interest): Put/Call OI ratio 0.04 → overwhelmingly call-heavy open interest (bullish/speculative skew).
Activity: Today’s options volume is 0 (calls 0, puts 0) → sentiment signal is not being reinforced by fresh flow.
Volatility: 30D IV ~565% vs historical vol ~83.5% (IV percentile ~66.5) → options are priced for extreme moves; not a “calm” accumulation profile.
Net read: Call-skewed OI is bullish on paper, but the lack of volume plus extreme IV makes it unreliable as a timing confirmation.

Technical Summary

Sell

Buy

Positive Catalysts

- Call-heavy options open interest suggests some participants are positioned for upside.
- Price is relatively close to first support (0.995), so a technical bounce is possible if that level holds.
- Pattern-based odds provided imply modest positive drift potential over 1W–1M (low magnitude).

Neutral/Negative Catalysts

- Strategic shift + massive dilution event: $212M private placement for 212M shares at $1.00 tied to a new digital-asset treasury strategy (RAIN tokens) is a major overhang and increases uncertainty about valuation and investor base.
- No recent news/catalysts in the past week to drive a near-term re-rating.
- Current session weakness: -2.75% regular session (and slightly red pre-market) while broader market is only mildly down.
- No Intellectia proprietary “strong buy” triggers today (AI Stock Picker and SwingMax both absent).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (no meaningful operating revenue).
Profitability: Net loss widened to -$2.205M (down 15.26% YoY).
EPS: -0.09 (down 25% YoY).
Takeaway: Financial trend remains loss-making with deterioration YoY; fundamentals do not currently support an “impatient buy-the-breakout” approach.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating change: On 2025-11-24, D. Boral Capital downgraded ENLV to Hold from Buy and removed a price target.
Rationale: Their prior valuation framework (therapeutics-driven) is now “less relevant” after the company’s pivot to a digital asset treasury strategy.
Wall Street-style pros: Potential optionality from a new treasury/crypto-linked strategy and speculative upside.
Wall Street-style cons: Valuation uncertainty, strategy execution risk, and dilution/financing overhang dominate near-term sentiment.
Influential/political activity: No recent congress trading data available; hedge funds and insiders are listed as neutral with no significant recent trends.

Analyst Rating

Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.160

Low

Averages

High

Current: 1.160

Low

Averages

High

D. Boral Capital

Buy -> Hold

downgrade

AI Analysis

2025-11-24

Reason

D. Boral Capital

Price Target

AI Analysis

2025-11-24

downgrade

Buy -> Hold

Reason

D. Boral Capital downgraded Enlivex Therapeutics to Hold from Buy with no price target after the company announced a $212M private placement for 212M shares priced at $1.00 to initiate a digital asset treasury strategy centered on the accumulation of RAIN tokens designed for on-chain predictive markets, options trading, and transparent data aggregation. The firm, which notes its valuation models had been based on the value of the therapeutic, says those are "less relevant now" and it needs some time to understand how to value the company following the shift.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$13

2025-04-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$13

2025-04-21

Maintains

Strong Buy

Reason

ENLV Should I Buy

ENLV Should I Buy

Should You Buy Enlivex Therapeutics Ltd (ENLV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch